Donate
Back to Clinical Trials
Back to Clinical Trials

Brief Title: Genetic Susceptibility to Bladder Cancer

Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach

INTRODUCTION

  • Org Study ID: LAB98-040
  • Secondary ID: N/A
  • NCT ID: NCT00848289
  • Sponsor: M.D. Anderson Cancer Center

BRIEF SUMMARY

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

DETAILED DESCRIPTION

Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

  • Overall Status
    Recruiting
  • Start Date
    February 10, 1998
  • Phase
  • Study Type
    Observational

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
* Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer

- * Subject is a Texas resident.

- * Subject can understand English or a qualified translator is available for the interview.

- * Subjects of any age, gender, or ethnicity are eligible to participate in the study.

- * Subject consents to participate in the study.
Exclusion Criteria:
* Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months.

- * Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Jian Gu, MD

Role: Principal Investigator

Affiliation: M.D. Anderson Cancer Center

Overall Contact

Name: Jian Gu, MD, Tao T Le, Program Director, Epidemiology

Phone: 713-792-3020

Email: jiangu@mdanderson.org, tle@mdanderson.org

LOCATION

Facility Status Contact

Read Our Stories